Search clinical trials for: Tobramycin inhalation powder

Total 4717 results

Novartis Pharmaceuticals

Completed

Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis (EAGER)

Cystic Fibrosis

United States, Germany, United Kingdom, Colombia, Spain, France, Netherlands, Israel, Canada, Italy, Chile, Australia, Hungary, Mexico
Novartis Pharmaceuticals

Completed

Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)

Cystic Fibrosis

Spain, Germany, Switzerland, United Kingdom, Ireland
Novartis Pharmaceuticals

Completed

Open Label Extension to Bridging Study CTBM100C2303

Cystic Fibrosis | Pseudomonas Aeruginosa

Russian Federation, Estonia
Novartis

Terminated

Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects (EVOLVE)

Cystic Fibrosis

United States, Argentina, Brazil, Bulgaria, Canada, Chile, Lithuania, Mexico
Novartis Pharmaceuticals

Completed

Second Open Label Extension to Bridging Study CTBM100C2303

Pseudomonas Aeruginosa | Pulmonary Infections

Russian Federation, Romania, Estonia, Latvia, Lithuania, Bulgaria, South Africa
Novartis Pharmaceuticals

Completed

A Study of Tobramycin Inhalation Powder From a Modified Manufacturing Process Versus Placebo (EDIT)

Cystic Fibrosis

Russian Federation, Egypt, Romania, Estonia, Latvia, Lithuania, Bulgaria, South Africa, India
Novartis Pharmaceuticals

Terminated

Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles

Cystic Fibrosis

United States
Erik Allen Jensen
University of Florida

Active, not recruiting

Inhaled Tobramycin in BPD

Bronchopulmonary Dysplasia

United States
Dartmouth-Hitchcock Medical Center
Novartis Pharmaceuticals

Terminated

Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung

Cystic Fibrosis

United States
University Medical Center Groningen

Recruiting

DPI-Tobra-Kind Cyclops® in Children With Cystic Fibrosis

Cystic Fibrosis

Netherlands
Washington University School of Medicine

Completed

Intraarticular Antibiotic in TKA

Antibotics in Cementless Knees

United States
National Institute of Diabetes and Digestive and...
National Center for Research Resources (NCRR)

Completed

A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis

Cystic Fibrosis

United States
Erasmus Medical Center
Chiesi Farmaceutici S.p.A.

Completed

Addition of Tobramycin Inhalation in the Treatment of Ventilator Associated Pneumonia (VAPORISE)

Ventilator Associated Pneumonia (VAP)

Spain, Netherlands
AlgiPharma AS
Imperial College London; Cystic Fibrosis Foundation; University Hospital of Cologne and other collaborators

Withdrawn

A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis (SMR3372)

Cystic Fibrosis

Germany
Qianfoshan Hospital

Active, not recruiting

A Study of the Clinical Benefit of Tobramycin Inhalation Solution

Bronchiectasis | Cystic Fibrosis | Lung Infection

China
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

Asthma | Chronic Obstructive Pulmonary Disease COPD

United States
University Medical Center Groningen

Completed

Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis

Bronchiectasis

Netherlands
Mannkind Corporation

Completed

A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males

Diabetes Mellitus, Type 2 | Healthy Males

Netherlands
Medical Center Alkmaar

Completed

Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis (BATTLE)

Non-CF Bronchiectasis

Netherlands
Mannkind Corporation

Completed

Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different Suppliers

Healthy Volunteers

United States
Novartis Pharmaceuticals

Completed

Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis

Cystic Fibrosis
GlaxoSmithKline

Completed

Long-term Safety Study for GSK573719/GW642444 in Japanese (DB2115362)

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Romania, Russian Federation, Ukraine, Argentina, Poland, Czechia
GlaxoSmithKline

Completed

A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Russian Federation, Chile, Poland, Mexico, Estonia, Korea, Republic of, Philippines
Gilead Sciences
Covance; ClinPhone, Inc.; Chiltern International Inc.

Completed

Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

Cystic Fibrosis

Belgium, France, Germany, Italy, Netherlands, Spain, United States, Ireland, United Kingdom, Portugal, Austria, Denmark, Switzerland
Novartis

Completed

Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis (ELITE)

Cystic Fibrosis
Mannkind Corporation

Completed

A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Netherlands
GlaxoSmithKline

Completed

Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Asthma

United States, Germany, Japan, Romania, Russian Federation, Poland
Guangzhou Institute of Respiratory Disease

Unknown

Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa (TORNASOL)

Pseudomonas Infections | Bronchiectasis Adult

China
Savara Inc.

Completed

AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis

Cystic Fibrosis | MRSA

United States, Canada
Mannkind Corporation

No longer available

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

Type 1 Diabetes | Type 2 Diabetes

United States
University Hospital Tuebingen

Completed

Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients (CotoCFII)

Cystic Fibrosis With Pulmonary Manifestations
GlaxoSmithKline

Completed

Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Asthma

United States, Germany, Japan, Romania, Ukraine, Poland
Savara Inc.
Cystic Fibrosis Foundation; Synteract, Inc.

Completed

Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

Cystic Fibrosis

United States
Bonnie Ramsey
National Heart, Lung, and Blood Institute (NHLBI)

Completed

OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis (OPTIMIZE)

Cystic Fibrosis

United States
Respirion Pharmaceuticals Pty Ltd

Recruiting

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

Pseudomonas Aeruginosa | Cystic Fibrosis Lung | Respiratory Infections, Recurrent, Chronic

United States, Australia
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Germany, Estonia, Chile, Netherlands, Peru, South Africa, Sweden, Mexico, United Kingdom, Italy, Philippines, Canada
GlaxoSmithKline

Completed

A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Australia, Argentina, Germany, Spain, South Africa, Mexico, Peru, Netherlands, Canada, United Kingdom, Denmark, Chile, Italy, Sweden
Gilead Sciences

Completed

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF (AZLI CAT)

Cystic Fibrosis

United States
Mannkind Corporation

Terminated

Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Insmed Incorporated

Completed

Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections

Pseudomonas Aeruginosa Infection

France, Poland, United Kingdom, Germany, Spain, Belgium, Bulgaria, Denmark, Greece, Canada, Netherlands, Hungary, Italy, Ireland, Sweden, Slovakia, Austria, Serbia
Chiesi Farmaceutici S.p.A.

Completed

Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler® Device or the Capsule for Oral Inhalation Via Aerolizer® Device

COPD

Belgium
Mannkind Corporation

Completed

Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function

Diabetes Mellitus | Mild Nephropathy | Moderate Nephropathy

United States
Mannkind Corporation

Completed

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

Diabetes Mellitus: Type 1

United States
GlaxoSmithKline

Completed

GSK573719 IV Enabling Study

Pulmonary Disease, Chronic Obstructive

United Kingdom
Mannkind Corporation

Completed

Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers

Pulmonary Arterial Hypertension

United States
Neutec Ar-Ge San ve Tic A.Ş

Completed

Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment

COPD

Turkey
Respira Therapeutics, Inc.

Completed

A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Australia
Mannkind Corporation

Completed

A Trial to Determine How Long Insulin and FDKP (the Molecule That Forms Technosphere Particles) Stays in the Lungs of Healthy Individuals After Inhalation of Technosphere® Insulin (TI) Powder Using Bronchoalveolar Lavage (BAL)

Healthy Subjects

United States
Respira Therapeutics, Inc.

Completed

A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234

Healthy Volunteer

Australia

3

Subscribe